Benzinga | Apr 26, 2021 10:12AM EDT

Mizuho Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $116

Mizuho analyst Vamil Divan maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and lowers the price target from $119 to $116.